In addition, experimental findings suggest that inhibiting PDE7A can effectively protect the SH-SY5Y cell injury model induced by 6-OHDA without compromising the anesthesia duration induced by ketamine and xylazine, indicating the potential of PDE7A inhibitors in treating neurological diseases with fewer undesirable reactions, such as emesis [16]. Here, PDE7A is linked to nervous system disorder.